AP
APYX.US Apyx Medical Inc
- Market cap
- USD 118M
- P/E
- -
- P/B
- 12.64x
- ROE
- -98.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is APYX.US undervalued?
Graham numberThe Graham number of Apyx Medical Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Apyx Medical Inc fundamental analysis
No fundamental analysis for Apyx Medical Inc yet.
Apyx Medical Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Apyx Medical Inc
Apyx Medical Corporation, an energy technology company, designs, develops, manufactures, and sells electrosurgical equipment and medical devices in the United States and internationally. The company operates through two segments: Surgical Aesthetics and Original Equipment Manufacturing (OEM). It offers helium plasma generator for the delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures; and a…
Full company profileApyx Medical Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Apyx Medical Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 36.6M | 38.9M | 16.7M | 28.2M | 27.7M | 48.5M | 44.5M | 52.3M | 48.1M | 52.8M | 53.9M |
| Gross Profit | 17.9M | 19.8M | 10.8M | 19.1M | 17.5M | 33.6M | 29.1M | 33.8M | 29.4M | 19.0M | 30.1M |
| Operating Income | -3.79M | -5.27M | -13.6M | -20.9M | -20.1M | -14.4M | -23.6M | -17.3M | -18.8M | -6.45M | -4.38M |
| EBITDA | -3.06M | -13.0M | -13.9M | -19.1M | -18.5M | -13.9M | -22.0M | -18.1M | -16.8M | -4.59M | -2.75M |
| Net Income | -3.95M | -5.06M | 64.0M | -19.7M | -11.9M | -15.2M | -23.2M | -18.7M | -23.5M | -11.2M | -9.51M |
| EPS | -0.14 | -0.16 | 1.86 | -0.58 | -0.35 | -0.44 | -0.67 | -0.54 | -0.66 | -0.27 | -0.21 |
| Balance Sheet | |||||||||||
| Total Assets | 35.1M | 31.0M | 95.6M | 84.7M | 74.1M | 68.7M | 51.8M | 79.2M | 64.8M | 66.8M | 61.7M |
| Total Liabilities | 8.89M | 8.96M | 7.84M | 13.4M | 10.3M | 14.7M | 14.0M | 52.3M | 50.5M | 52.0M | 51.6M |
| Shareholders' Equity | 26.2M | 22.0M | 87.8M | 71.3M | 63.7M | 53.7M | 37.6M | 26.7M | 14.2M | 14.5M | 9.63M |
| Cash & Short-term Investments | 14.5M | 9.95M | 78.1M | 58.8M | 41.9M | 30.9M | 10.2M | 43.7M | 31.7M | 31.7M | 25.8M |
| Total Debt | 3.07M | 2.83M | 140K | 1.13M | 676K | 305K | 796K | 38.5M | 38.8M | 39.3M | 39.7M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -2.84M | -3.70M | -21.0M | -18.5M | -16.1M | -10.4M | -20.3M | -5.25M | -18.0M | -8.00M | -7.59M |
| Capital Expenditure | 286K | 624K | 363K | 1.30M | 581K | 723K | 1.01M | 533K | 722K | 1.11M | 521K |
| Free Cash Flow | -3.12M | -4.33M | -21.4M | -19.8M | -16.6M | -11.2M | -21.3M | -5.78M | -18.8M | -9.12M | -8.12M |
| Ratios | |||||||||||
| ROE | -15.1% | -23.0% | 72.9% | -27.7% | -18.7% | -28.3% | -61.7% | -70.1% | -165.1% | -77.1% | -98.8% |
| ROA | -11.3% | -16.3% | 66.9% | -23.3% | -16.1% | -22.1% | -44.8% | -23.6% | -36.2% | -16.8% | -15.4% |
| Net Profit Margin | -10.8% | -13.0% | 383.6% | -69.8% | -42.9% | -31.3% | -52.1% | -35.7% | -48.8% | -21.2% | -17.7% |
| Debt to Equity | 0.12x | 0.13x | 0.00x | 0.02x | 0.01x | 0.01x | 0.02x | 1.44x | 2.73x | 2.71x | 4.13x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Apyx Medical Inc dividends
Apyx Medical Inc has not paid dividends in the last 9 fiscal years.
Who owns Apyx Medical Inc
- Insiders 13.55%
- Institutions 53.38%
- Public & others 33.07%
- Shares outstanding 42.1M
- Free float 30.5M
Top funds holding APYX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Royce Micro-Cap Trust | 1.15M | 2.72% | +17.65% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 1.10M | 2.60% | 0.00% | Sep 2026 |
| Royce Small-Cap Opportunity Invmt | 768K | 1.82% | +9.04% | Sep 2026 |
| FTGF RY US SmCp Opp A USD Dis(A) | 717K | 1.70% | -7.98% | Sep 2026 |
| Royce Micro-Cap Invmt | 613K | 1.46% | +4.52% | Sep 2026 |
| Philotimo Focused Growth and Income | 376K | 0.89% | 0.00% | Sep 2026 |
| 1290 Essex Small Cap Growth I | 278K | 0.66% | +0.53% | Sep 2026 |
| Royce Capital Micro-Cap Inv | 221K | 0.52% | +2.65% | Sep 2026 |
| Fidelity Extended Market Index | 176K | 0.42% | -0.38% | Sep 2026 |
| Taylor Frigon Core Growth | 128K | 0.30% | 0.00% | Aug 2026 |
| iShares Micro-Cap ETF | 109K | 0.26% | 0.00% | Oct 2026 |
| Fidelity Total Market Index | 64.6K | 0.15% | -0.05% | Sep 2026 |
| Fidelity Series Total Market Index | 55.1K | 0.13% | 0.00% | Sep 2026 |
| EA Bridgeway Ultra-Small Company Mkt ETF | 53.8K | 0.13% | 0.00% | Oct 2026 |
| Fidelity Nasdaq Composite Index | 28.1K | 0.07% | 0.00% | Aug 2026 |
| Venerable US Small Cap V | 22.0K | 0.05% | 0.00% | Sep 2026 |
| Vanguard Balanced Index Inv | 21.4K | 0.05% | 0.00% | Sep 2026 |
| Vanguard MStar Inst Ttl StkMktIdxInstlPl | 18.3K | 0.04% | 0.00% | Sep 2026 |
Top institutions holding APYX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Nantahala Capital Management, LLC | 6.54M | 15.53% | +90.11% | Jun 2026 |
| Royce & Associates, LP | 3.27M | 7.77% | +25.38% | Jun 2026 |
| Archon Capital Management LLC | 2.64M | 6.28% | -5.24% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.53M | 3.64% | -1.31% | Jun 2026 |
| Essex Investment Management Company, LLC | 1.14M | 2.70% | +26.10% | Jun 2026 |
| AIGH Capital Management, LLC | 1.13M | 2.68% | +2.12% | Jun 2026 |
| Silverberg Bernstein Capital Management LLC | 1.02M | 2.43% | -1.67% | Sep 2026 |
| Commonwealth Equity Services, LLC | 649K | 1.54% | 0.00% | Jun 2026 |
| Horizon Asset Management Inc/ny | 585K | 1.39% | -4.88% | Jun 2026 |
| BlackRock Inc | 561K | 1.33% | +6.30% | Jun 2026 |
| Renaissance Technologies Corp | 554K | 1.32% | +83.30% | Jun 2026 |
| Taylor Frigon Capital Management LLC | 414K | 0.98% | -0.23% | Jun 2026 |
| Geode Capital Management, LLC | 401K | 0.95% | +2.36% | Jun 2026 |
| Legato Capital Management LLC | 383K | 0.91% | +36.27% | Jun 2026 |
| SEI Investments Co | 281K | 0.67% | -53.03% | Jun 2026 |
| Huntleigh Advisors Inc | 263K | 0.62% | +7.04% | Jun 2026 |
| Millennium Management LLC | 243K | 0.58% | -7.40% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 236K | 0.56% | +282.41% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 224K | 0.53% | +10.53% | Jun 2026 |
| Susquehanna International Group, LLP | 216K | 0.51% | -19.17% | Jun 2026 |
Apyx Medical Inc company profile
- Company name
- Apyx Medical Inc
- Ticker
- APYX.US
- Exchange
- USA Stocks
- Listed since
- Jan 1, 1987
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 205
- Fiscal year end
- December
- Address
- 5115 Ulmerton Road, Clearwater, FL, United States, 33760-4004
- Phone
- 727 384 2323
- Website
- apyxmedical.com
About Apyx Medical Inc
Apyx Medical Corporation, an energy technology company, designs, develops, manufactures, and sells electrosurgical equipment and medical devices in the United States and internationally. The company operates through two segments: Surgical Aesthetics and Original Equipment Manufacturing (OEM). It offers helium plasma generator for the delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures; and a portfolio of single-use handpieces and accessories for open and laparoscopic procedures. The company's helium plasma technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures OEM generators and related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
Apyx Medical Inc management
5- Mr. Charles D. Goodwin IIPresident, CEO & Director · born 1966
- Mr. Matthew C. Hill CPACFO, Treasurer & Secretary · born 1969
- Mr. Shawn D. RomanChief Operating Officer · born 1972
- Mr. Moshe CitronowiczSenior Vice President · born 1953
- Ms. Dolores CataniaChief of Confidence